
Jörg Ellinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5996906/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Androgen Receptor Coactivators Lysine-Specific Histone Demethylase 1 and Four and a Half LIM Domain Protein 2 Predict Risk of Prostate Cancer Recurrence. Cancer Research, 2006, 66, 11341-11347.	0.9	437
2	Circulating microRNAs (miRNA) in Serum of Patients With Prostate Cancer. Urology, 2011, 77, 1265.e9-1265.e16.	1.0	210
3	MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of Serum miR-1233 Levels. PLoS ONE, 2011, 6, e25787.	2.5	202
4	Global levels of histone modifications predict prostate cancer recurrence. Prostate, 2010, 70, 61-69.	2.3	194
5	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 2016, 22, 1969-1977.	7.0	170
6	Circulating Serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as Biomarkers in Patients with Testicular Germ Cell Cancer. Journal of Urology, 2015, 193, 331-337.	0.4	169
7	Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci. Clinical Cancer Research, 2005, 11, 4097-4106.	7.0	135
8	CpG Island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate, 2008, 68, 42-49.	2.3	121
9	CpG Island Hypermethylation at Multiple Gene Sites in Diagnosis and Prognosis of Prostate Cancer. Urology, 2008, 71, 161-167.	1.0	120
10	Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer and Prostatic Diseases, 2008, 11, 6-12.	3.9	115
11	Association Between the Number of Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific Survival in Patients with Lymph Node–Negative Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. Annals of Surgical Oncology, 2011, 18, 2018-2025.	1.5	112
12	Primitive neuroectodermal tumor: Rare, highly aggressive differential diagnosis in urologic malignancies. Urology, 2006, 68, 257-262.	1.0	109
13	Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?. World Journal of Urology, 2014, 32, 353-358.	2.2	108
14	Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. International Journal of Cancer, 2010, 127, 2360-2366.	5.1	101
15	Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiology, 2012, 36, 391-394.	1.9	101
16	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clinical Chemistry, 2017, 63, 1288-1296.	3.2	97
17	H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Human Pathology, 2010, 41, 181-189.	2.0	93
18	Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 509-515.	1.6	90

#	Article	IF	CITATIONS
19	Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. International Journal of Cancer, 2008, 122, 138-143.	5.1	87
20	Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clinical Epigenetics, 2018, 10, 11.	4.1	87
21	Circulating mitochondrial DNA in the serum of patients with testicular germ cell cancer as a novel noninvasive diagnostic biomarker. BJU International, 2009, 104, 48-52.	2.5	84
22	Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma. Cancer Science, 2010, 101, 2664-2669.	3.9	84
23	Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. International Journal of Urology, 2012, 19, 1017-1025.	1.0	84
24	Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy. BJU International, 2008, 102, 628-632.	2.5	81
25	Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular Germ Cell Cancer. Journal of Urology, 2009, 181, 363-371.	0.4	79
26	CpG Island Hypermethylation of Cell-Free Circulating Serum DNA in Patients With Testicular Cancer. Journal of Urology, 2009, 182, 324-329.	0.4	77
27	Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. Clinical Epigenetics, 2015, 7, 10.	4.1	77
28	Lymph Node Density Affects Cancer-Specific Survival in Patients with Lymph Node–Positive Urothelial Bladder Cancer Following Radical Cystectomy. European Urology, 2011, 59, 712-718.	1.9	76
29	<i>PD-L1</i> promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget, 2016, 7, 79943-79955.	1.8	73
30	Prognostic Value of CpG Island Hypermethylation at PTGS2, RAR-beta, EDNRB, and Other Gene Loci in Patients Undergoing Radical Prostatectomy. European Urology, 2007, 51, 665-674.	1.9	72
31	Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. Journal of Urology, 2018, 199, 370-377.	0.4	71
32	<i>LAG3</i> (<i>LAG-3</i> , <i>CD223</i>) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. , 2020, 8, e000552.		70
33	KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy. American Journal of Pathology, 2014, 184, 2430-2437.	3.8	69
34	Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU International, 2011, 108, E290-E296.	2.5	68
35	Hypermethylation of Cell-Free Serum DNA Indicates Worse Outcome in Patients With Bladder Cancer. Journal of Urology, 2008, 179, 346-352.	0.4	66
36	Analysis of Sex Differences in Cancer-Specific Survival and Perioperative Mortality Following Radical Cystectomy: Results of a Large German Multicenter Study of Nearly 2500 Patients with Urothelial Carcinoma of the Bladder. Gender Medicine, 2012, 9, 481-489.	1.4	65

#	Article	IF	CITATIONS
37	The <i>N</i> ⁶ â€methyladenosine (m ⁶ A) erasers alkylation repair homologue 5 (ALKBH5) and fat mass and obesityâ€associated protein (FTO) are prognostic biomarkers in patients with clear cell renal carcinoma. BJU International, 2020, 125, 617-624.	2.5	65
38	Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: A prognostic entity. Cancer Letters, 2008, 264, 274-280.	7.2	61
39	Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. Scientific Reports, 2016, 6, 37158.	3.3	59
40	Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU International, 2012, 109, 459-465.	2.5	58
41	Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1141-1147.	1.6	55
42	Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Review of Molecular Diagnostics, 2015, 15, 505-516.	3.1	54
43	Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma. Molecular Cancer, 2016, 15, 10.	19.2	53
44	Global Histone H3K27 Methylation Levels are Different in Localized and Metastatic Prostate Cancer. Cancer Investigation, 2012, 30, 92-97.	1.3	51
45	Testicular seminoma clinical stage 1: treatment outcome on a routine care level. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1599-1607.	2.5	48
46	Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma. Translational Oncology, 2017, 10, 661-668.	3.7	48
47	Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Human Pathology, 2008, 39, 1597-1605.	2.0	47
48	The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 124-129.	1.6	47
49	Rationale for Treatment of Metastatic Squamous Cell Carcinoma of the Lung Using Fibroblast Growth Factor Receptor Inhibitors. Chest, 2012, 142, 1020-1026.	0.8	47
50	Tomatoes, tomato products and lycopene in the prevention and treatment of prostate cancer: do we have the evidence from intervention studies?. Current Opinion in Clinical Nutrition and Metabolic Care, 2006, 9, 722-727.	2.5	46
51	Alterations of global histone H4K20 methylation during prostate carcinogenesis. BMC Urology, 2012, 12, 5.	1.4	46
52	Kinetics of ÊŸ-Theanine Uptake and Metabolism in Healthy Participants Are Comparable after Ingestion of ÊŸ-Theanine via Capsules and Green Tea4. Journal of Nutrition, 2012, 142, 2091-2096.	2.9	43
53	Promoter methylation of the immune checkpoint receptor <i>PD-1</i> (<i>PDCD1</i>) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncolmmunology, 2016, 5, e1221555.	4.6	43
54	5′-tRNA Halves are Dysregulated in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2018, 199, 378-383.	0.4	43

#	Article	IF	CITATIONS
55	Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Research, 2013, 33, 4651-6.	1.1	43
56	Analysis of Tissue and Serum MicroRNA Expression in Patients with Upper Urinary Tract Urothelial Cancer. PLoS ONE, 2015, 10, e0117284.	2.5	42
57	The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key?. Molecular Medicine Reports, 2012, 5, 313-6.	2.4	41
58	ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development. Scientific Reports, 2017, 7, 42170.	3.3	41
59	PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. Journal of Molecular Diagnostics, 2017, 19, 107-114.	2.8	41
60	Thulium Laser (Revolix) Vapoenucleation of the Prostate Is a Safe Procedure in Patients with an Increased Risk of Hemorrhage. Urologia Internationalis, 2012, 88, 390-394.	1.3	39
61	Tyrosine kinase expression profile in clear cell renal cell carcinoma. World Journal of Urology, 2012, 30, 559-565.	2.2	38
62	C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. , 2022, 10, e004024.		38
63	<i>CXCL12</i> promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. Oncotarget, 2016, 7, 53309-53320.	1.8	37
64	<i>CDO1</i> promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients. Epigenetics, 2016, 11, 871-880.	2.7	37
65	Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study. Anticancer Research, 2014, 34, 665-9.	1.1	37
66	Nucleic acid-based tissue biomarkers of urologic malignancies. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 173-199.	6.1	33
67	Evidence from the â€ ⁻ PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' Study: How are Preoperative Patient Characteristics Associated with Urinary Diversion Type After Radical Cystectomy for Bladder Cancer?. Annals of Surgical Oncology, 2015, 22, 1032-1042.	1.5	33
68	Identification of novel differentially expressed IncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. Genomics Data, 2015, 5, 173-175.	1.3	32
69	Alterations of Global Histone H3K9 and H3K27 Methylation Levels in Bladder Cancer. Urologia Internationalis, 2014, 93, 113-118.	1.3	31
70	The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. American Journal of Cancer Research, 2015, 5, 2799-807.	1.4	31
71	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. World Journal of Urology, 2015, 33, 1945-1950.	2.2	28
72	Influence of Body Mass Index on Clinical Outcome Parameters, Complication Rate and Survival after Radical Cystectomy: Evidence from a Prospective European Multicentre Study. Urologia Internationalis, 2018, 101, 16-24.	1.3	28

Jörg Ellinger

#	Article	IF	CITATIONS
73	Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR-γ) in advanced prostate cancer. Anticancer Research, 2012, 32, 3479-83.	1.1	28
74	Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, 209-217.	2.5	26
75	Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma. Oncotarget, 2016, 7, 86490-86499.	1.8	26
76	DNA hypermethylation in papillary renal cell carcinoma. BJU International, 2011, 107, 664-669.	2.5	25
77	YRNA expression predicts survival in bladder cancer patients. BMC Cancer, 2017, 17, 749.	2.6	25
78	tRNA-halves are prognostic biomarkers for patients with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 503.e1-503.e7.	1.6	25
79	Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Research, 2012, 32, 879-86.	1.1	25
80	Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. Frontiers in Oncology, 2020, 10, 1775.	2.8	24
81	Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types. Oncotarget, 2016, 7, 23043-23055.	1.8	24
82	Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study. Anticancer Research, 2013, 33, 779-84.	1.1	24
83	Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e551-e562.	1.9	23
84	Apelin and apelin receptor expression in renal cell carcinoma. British Journal of Cancer, 2019, 120, 633-639.	6.4	22
85	Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma. World Journal of Urology, 2019, 37, 1639-1647.	2.2	22
86	<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. , 2021, 9, e002949.		22
87	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817.	1.9	21
88	Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology, 2011, 45, 251-257.	1.4	20
89	Prediction of outcome in patients with urothelial carcinoma of the bladder following radical cystectomy using artificial neural networks. European Journal of Surgical Oncology, 2013, 39, 372-379.	1.0	20
90	Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. Cancers, 2020, 12, 2471.	3.7	20

#	Article	IF	CITATIONS
91	Bolus Consumption of a Specifically Designed Fruit Juice Rich in Anthocyanins and Ascorbic Acid Did Not Influence Markers of Antioxidative Defense in Healthy Humans. Journal of Agricultural and Food Chemistry, 2012, 60, 11292-11300.	5.2	19
92	The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma. Expert Review of Molecular Diagnostics, 2016, 16, 1059-1065.	3.1	19
93	N ⁶ â€Methyladenosine (m ⁶ A) readers are dysregulated in renal cell carcinoma. Molecular Carcinogenesis, 2021, 60, 354-362.	2.7	19
94	¹⁷⁷ Lu-Prostate-Specific Membrane Antigen Ligand After ²²³ Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. Journal of Nuclear Medicine, 2022, 63, 410-414.	5.0	19
95	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. Clinical Genitourinary Cancer, 2021, 19, 469-479.	1.9	19
96	Epigenetic regulation of microRNA expression in renal cell carcinoma. Biochemical and Biophysical Research Communications, 2013, 436, 79-84.	2.1	18
97	YRNA Expression Profiles are Altered in Clear Cell Renal Cell Carcinoma. European Urology Focus, 2018, 4, 260-266.	3.1	18
98	CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma. Cancers, 2021, 13, 2177.	3.7	18
99	ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 1117.	4.1	18
100	Comparison of Myocardial Remodeling between Cryoinfarction and Reperfused Infarction in Mice. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-10.	3.0	17
101	YRNA expression in prostate cancer patients: diagnostic and prognostic implications. World Journal of Urology, 2018, 36, 1073-1078.	2.2	17
102	Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. Clinical Chemistry, 2019, 65, 559-568.	3.2	17
103	DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype. Current Genomics, 2020, 21, 34-36.	1.6	17
104	Multicenter evaluation of the prognostic value of pTO stage after radical cystectomy due to urothelial carcinoma of the bladder. BJU International, 2011, 108, E278-E283.	2.5	16
105	PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy. Clinical Epigenetics, 2016, 8, 104.	4.1	16
106	Prognostic role of TSPAN1, KIAA1324 and ESRP1 in prostate cancer. Apmis, 2021, 129, 204-212.	2.0	16
107	Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients. Anticancer Research, 2016, 36, 3961-4.	1.1	16
108	Seminoma Clinical Stage 1 - Patterns of Care in Germany. Urologia Internationalis, 2016, 96, 390-398.	1.3	15

#	Article	IF	CITATIONS
109	The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma. Clinical and Translational Oncology, 2020, 22, 1524-1531.	2.4	15
110	Câ€reactive protein flareâ€response predicts longâ€term efficacy to firstâ€line antiâ€PDâ€1â€based combination therapy in metastatic renal cell carcinoma. Clinical and Translational Immunology, 2021, 10, e1358.	3.8	15
111	C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma. European Journal of Cancer, 2022, 167, 13-22.	2.8	15
112	Mediator Complex Subunit MED1 Protein Expression Is Decreased during Bladder Cancer Progression. Frontiers in Medicine, 2017, 4, 30.	2.6	13
113	Saturation biopsy improves preoperative Gleason scoring of prostate cancer. Pathology Research and Practice, 2009, 205, 259-264.	2.3	11
114	Clutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide. Biochemical and Biophysical Research Communications, 2011, 412, 606-611.	2.1	11
115	Expression of programmed cell death protein 4 (PDCD4) and miR-21 in urothelial carcinoma. Biochemical and Biophysical Research Communications, 2012, 417, 29-34.	2.1	11
116	External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder. European Journal of Surgical Oncology, 2012, 38, 637-642.	1.0	11
117	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. Diagnostic Pathology, 2015, 10, 165.	2.0	11
118	Low Plasma Appearance of (+)-Catechin and (â^')-Catechin Compared with Epicatechin after Consumption of Beverages Prepared from Nonalkalized or Alkalized Cocoa—A Randomized, Double-Blind Trial. Nutrients, 2020, 12, 231.	4.1	11
119	Histone Methylation Defines an Epigenetic Entity in Penile Squamous Cell Carcinoma. Journal of Urology, 2013, 189, 1117-1122.	0.4	10
120	Classic bladder exstrophy and adenocarcinoma of the bladder: Methylome analysis provide no evidence for underlying disease-mechanisms of this association. Cancer Genetics, 2019, 235-236, 18-20.	0.4	10
121	Systematic expression analysis of the mitochondrial respiratory chain protein subunits identifiesCOX5Bas a prognostic marker in clear cell renal cell carcinoma. International Journal of Urology, 2019, 26, 910-916.	1.0	10
122	Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e167-e175.	1.9	10
123	Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. Translational Andrology and Urology, 2020, 9, 1314-1322.	1.4	10
124	Targeting glycolysis with 2-deoxy-d-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2255-2265.	2.5	10
125	Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression. Oncotarget, 2017, 8, 75076-75086.	1.8	10
126	Systemic Effects Reflected in Specific Biomarker Patterns Are Instrumental for the Paradigm Change in Prostate Cancer Management: A Strategic Paper. Cancers, 2022, 14, 675.	3.7	10

#	Article	IF	CITATIONS
127	The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma. Cancer Biomarkers, 2018, 21, 839-847.	1.7	9
128	Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer. American Journal of Cancer Research, 2014, 4, 952-62.	1.4	9
129	MicroRNA-profiling of miR-371~373- and miR-302/367-clusters in serum and cerebrospinal fluid identify patients with intracranial germ cell tumors. Journal of Cancer Research and Clinical Oncology, 2023, 149, 791-802.	2.5	9
130	Downstream neighbor of SON (DONSON) is associated with unfavorable survival across diverse cancers with oncogenic properties in clear cell renal cell carcinoma. Translational Oncology, 2020, 13, 100844.	3.7	8
131	Systematic expression analysis of m 6 A RNA methyltransferases in clear cell renal cell carcinoma. BJUI Compass, 2021, 2, 402-411.	1.3	8
132	NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival. American Journal of Cancer Research, 2015, 5, 2816-22.	1.4	8
133	External Validation of a Risk Model to Predict Recurrence-Free Survival After Radical Cystectomy in Patients With Pathological Tumor Stage T3N0 Urothelial Carcinoma of the Bladder. Journal of Urology, 2012, 187, 1210-1214.	0.4	7
134	Spindle cell rhabdomyosarcoma of the prostate. International Journal of Urology, 2013, 20, 935-937.	1.0	7
135	Downstream Neighbor of SON (DONSON) Expression Is Enhanced in Phenotypically Aggressive Prostate Cancers. Cancers, 2020, 12, 3439.	3.7	7
136	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. American Journal of Pathology, 2021, 191, 618-630.	3.8	7
137	MicroRNAs: A Novel Non-Invasive Biomarker for Patients with Urological Malignancies. Current Pharmaceutical Biotechnology, 2014, 15, 486-491.	1.6	7
138	Comprehensive Analysis of the ATP-binding Cassette Subfamily B Across Renal Cancers Identifies ABCB8 Overexpression in Phenotypically Aggressive Clear Cell Renal Cell Carcinoma. European Urology Focus, 2020, 7, 1121-1129.	3.1	6
139	Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. International Journal of Urology, 2021, 28, 424-431.	1.0	6
140	CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC. Cancers, 2022, 14, 1541.	3.7	6
141	Comprehensive Analysis of N6-Methyladenosine (m6A) Writers, Erasers, and Readers in Cervical Cancer. International Journal of Molecular Sciences, 2022, 23, 7165.	4.1	6
142	Genes differentially expressed in the peripheral zone compared to the transitional zone of the normal human prostate and their potential regulation by ETS factors. Molecular Medicine Reports, 2011, 5, 32-6.	2.4	5
143	Identification of immunity-related genes in prostate cancer and potential role of the ETS family of transcription factors in their regulation. International Journal of Molecular Medicine, 2011, 28, 799-807.	4.0	5
144	Identification of prostaglandin receptors in human ureters. BMC Urology, 2012, 12, 35.	1.4	5

#	Article	IF	CITATIONS
145	Pathological Outcomes of Men Eligible for Active Surveillance After Undergoing Radical Prostatectomy: Are Results Predictable?. Clinical Genitourinary Cancer, 2012, 10, 32-36.	1.9	5
146	Mitophagy-associated genes PINK1 and PARK2 are independent prognostic markers of survival in papillary renal cell carcinoma and associated with aggressive tumor behavior. Scientific Reports, 2020, 10, 18857.	3.3	5
147	Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort. Urologia Internationalis, 2022, 106, 1150-1157.	1.3	5
148	Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2417-2424.	2.5	5
149	Cytoplasmatic and Nuclear YAP1 and pYAP1 Staining in Urothelial Bladder Cancer. Urologia Internationalis, 2016, 96, 39-45.	1.3	4
150	The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells. Annals of Diagnostic Pathology, 2018, 34, 18-26.	1.3	4
151	The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy. Oncology Letters, 2018, 16, 3013-3021.	1.8	4
152	Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer. In Vivo, 2019, 33, 1935-1940.	1.3	4
153	The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 687.e1-687.e11.	1.6	4
154	Pelvic Exenteration in Advanced Gynecologic Malignancies – Who Will Benefit?. Anticancer Research, 2021, 41, 3037-3043.	1.1	4
155	The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer. Anticancer Research, 2017, 37, 6685-6695.	1.1	4
156	Clinical and pathological nodal staging score for urothelial carcinoma of the bladder: an external validation. World Journal of Urology, 2014, 32, 365-371.	2.2	3
157	Fungaemia caused by obstructive renal candida bezoars leads to bilateral chorioretinitis: a case report. BMC Urology, 2018, 18, 21.	1.4	3
158	Diagnostic Meaning of Urodynamic Studies in Pouch Incontinence: Results of a Small Series. Urologia Internationalis, 2014, 92, 237-241.	1.3	2
159	High grade adenocarcinoma in the ectopic prostate accompanied by a low grade adenocarcinoma in the orthotopic prostate: an unusual diagnostic pitfall. Pathology, 2017, 49, 665-668.	0.6	2
160	Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223) Journal of Clinical Oncology, 2020, 38, e17592-e17592.	1.6	2
161	Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer. Current Cancer Therapy Reviews, 2014, 9, 258-264.	0.3	1
162	First report of an unexpected blind-ending duplication of the ureter as a rare pitfall in kidney transplantation. Transplant International, 2008, 21, 696-697.	1.6	0

#	Article	IF	CITATIONS
163	A NOVEL DIAGNOSTIC MARKER: CELL-FREE CIRCULATING DNA IN SERUM OF PATIENTS WITH TESTICULAR CANCER. Journal of Urology, 2008, 179, 272-272.	0.4	0
164	HYPERMETHYLATION IN CELL-FREE CIRCULATING SERUM DNA IDENTIFIES PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal of Urology, 2008, 179, 720-721.	0.4	0
165	Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report. Urologia Internationalis, 2016, 97, 369-372.	1.3	0
166	Programmed Cell Death Protein 4 -Expression in Urologic Tumors. The Open Prostate Cancer Journal, 2014, 7, 7-11.	0.4	0
167	RNA Sequencing Reveals Alterations and Similarities in Cell Metabolism, Hypoxia and Immune Evasion in Primary Cell Cultures of Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2022, 12, .	2.8	0